Famar will consider more plant acquisitions in Europe and North America

By Gareth Macdonald contact

- Last updated on GMT

iStock/Harvepino
iStock/Harvepino

Related tags: Europe, North america, United states

Famar has said it will consider buying other US FDA approved facilities in Europe and North America.

The Paris-based contract manufacturing organisation (CMO) announced the plan after revealing​ it will buy an oral solid dose facility in Leganés, Spain from Roche.

COO Jeff Morrod told us acquiring the US compliant facility fits with Famar’s growth strategy.

"We liked the product portfolio [made at the Leganés facility] and we liked that the fact it is US FDA compliant​."

He added that: “We will consider buying more facilities in Europe and the US in line with our growth strategy, part of which is to expand our business in North America​.”

Famar is unlikely to buy any facilities in Asia according to Morrod, who said: “While I would never rule anything out, we are focused on expanding our manufacturing capacity, capabilities and business in Europe and North America."

The CMO will take posession of the Roche site on July 1.

It will add a second US FDA compliant facility next January when it buys a facility in Pointe-Claire, Quebec, Canada from Germany’s Bayer.

Strategic relationship

Buying the Leganés facility is about more than Famar’s North American growth ambitions.

According to Morrod the deal – which will see it supply Roche with products made at the site – has established the CMO as a strategic partner.

It is important for Famar to have a strong relationship with Roche​” he said, explaining that “previously we have not done a lot of work with Roche. Buying this facility establishes us a strategic partner​.”

He also confirmed that the 249 staff Roche employs at the facility will be joining Famar.

The facility is near a plant in Alcorcon that Famar bought from French drug manufacturer Sanofi in 2011.

Related news

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Related suppliers

Follow us

Products

View more